<DOC>
	<DOCNO>NCT01202630</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy BIO-K+ CL1285 prevention recurrent Clostridium difficile infection .</brief_summary>
	<brief_title>BIO-K+ CL1285 Prevention Recurrent Clostridium Difficile Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>1 . Age 18 year old 2 . Presence two loose liquid stool 24hour period prior initiation antibiotic therapy 3 . Hospitalized start antibiotic therapy Clostridium difficile infection ( CDI ) recurrent Clostridium difficile infection ( RCDI ) , diagnose positive stool culture 4 . Agree use contraception throughout study period , unless postmenopausal surgically sterile ( female ) 5 . Understand nature purpose study include potential risk side effect 6 . Willing comply requirement study 1 . History 2 clostridium difficile infection time prior current episode 2 . Presence severe chronic and/or inflammatory condition 3 . Impaired immunity , e.g . undergoing immunotherapy chemotherapy 4 . Major gastrointestinal complication , e.g . Crohn 's disease ulcer 5 . Current treatment nasogastric tube , ostomy , parenteral nutrition 6 . Use proton pump inhibitor 7 . Pregnant female breastfeed 8 . Eating disorder 9 . History alcohol , drug , medication abuse 10 . Daily consumption probiotic , ferment milk , and/or yogurt 11 . Known allergy substance study product 12 . Participation another study investigational product within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Clostridium difficile</keyword>
	<keyword>diarrhea</keyword>
</DOC>